Sulfenic acid modification of endothelin b receptor is responsible for the benefit of a nonsteroidal mineralocorticoid receptor antagonist in renal ischemia

Journal of the American Society of Nephrology

Volumn 27, Issue 2, 2016, Pages 398-404

  Barrera Chimal, Jonatan ^a   Prince, Sonia ^a   Fadel, Fouad ^a   El Moghrabi, Soumaya ^a   Warnock, David G ^b   Kolkhof, Peter ^c   Jaisser, Frédéric ^a  

^a INSERM   (France)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c BAYER PHARMA AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BR 4628; CASPASE 3; CD68 ANTIGEN; CREATININE; CYSTEINE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIN B RECEPTOR; HEAT SHOCK PROTEIN 72; HYDROGEN PEROXIDE; KIDNEY INJURY MOLECULE 1; MINERALOCORTICOID ANTAGONIST; N (2,6 DIMETHYLPIPERIDINOCARBONYL) 4 METHYLLEUCYL DEXTRO (1 METHOXYCARBONYLTRYPTOPHANYL) DEXTRO NORLEUCINE; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; NITRATE; NITRITE; PROTEIN; PROTEIN KIM 1; SULFENIC ACID DERIVATIVE; UNCLASSIFIED DRUG; BR-4628; CHROMONE DERIVATIVE; DIHYDROPYRIDINE DERIVATIVE;

ACUTE KIDNEY FAILURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHEMICAL MODIFICATION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE URINE LEVEL; DISEASE ASSOCIATION; ENZYME ACTIVATION; KIDNEY BLOOD FLOW; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; KIDNEY ISCHEMIA; KIDNEY TUBULE DAMAGE; KIDNEY VASCULAR RESISTANCE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RENAL PROTECTION; ANIMAL; DRUG EFFECTS; KIDNEY; REPERFUSION INJURY; VASCULARIZATION; WISTAR RAT;

ANIMALS; CHROMONES; DIHYDROPYRIDINES; KIDNEY; MALE; MINERALOCORTICOID RECEPTOR ANTAGONISTS; RATS; RATS, WISTAR; RECEPTOR, ENDOTHELIN B; REPERFUSION INJURY; SULFENIC ACIDS;

EID: 84970925334     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2014121216     Document Type: Article

References (29)

1. Lewington AJ, Cerdá J, Mehta RL: Raising awareness of acute kidney injury: a global perspective of a silent killer. Kidney Int 84: 457-467, 2013
2. Mehta RL, Pascual MT, Soroko S, Savage BR, Himmelfarb J, Ikizler TA, Paganini EP, Chertow GM; Program to Improve Care in Acute Renal Disease: Spectrumof acute renal failure in the intensive care unit: the PICARD experience. Kidney Int 66: 1613-1621, 2004
3. Kinsey GR,OkusaMD: Pathogenesis of acute kidney injury: foundation for clinical practice. Am J Kidney Dis 58: 291-301, 2011
4. Jo SK, Rosner MH, Okusa MD: Pharmacologic treatment of acute kidney injury: why drugs haven't worked and what is on the horizon. Clin J Am Soc Nephrol 2: 356-365, 2007
5. Bonventre JV, Yang L: Cellular pathophysiology of ischemic acute kidney injury. J Clin Invest 121: 4210-4221, 2011
6. Sharfuddin AA, Molitoris BA: Pathophysiology of ischemic acute kidney injury. Nat Rev Nephrol 7: 189-200, 2011
7. Sutton TA, Fisher CJ, Molitoris BA: Microvascular endothelial injury and dysfunction during ischemic acute renal failure. Kidney Int 62: 1539-1549, 2002
8. Phillips L, Toledo AH, Lopez-Neblina F, Anaya-Prado R, Toledo-Pereyra LH: Nitric oxide mechanism of protection in ischemia and reperfusion injury. J Invest Surg 22: 46-55, 2009
9. Mejía-Vilet JM, Ramírez V, Cruz C, Uribe N, Gamba G, Bobadilla NA: Renal ischemiareperfusion injury is prevented by the mineralocorticoid receptor blocker spironolactone. Am J Physiol Renal Physiol 293: F78-F86, 2007
10. Sánchez-Pozos K, Barrera-Chimal J, Garzón-Muvdi J, Pérez-Villalva R, Rodríguez-Romo R, Cruz C, Gamba G, Bobadilla NA: Recovery from ischemic acute kidney injury by spironolactone administration. Nephrol Dial Transplant 27: 3160-3169, 2012
11. Weir MR, Rolfe M: Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors. Clin J Am Soc Nephrol 5: 531-548, 2010
12. Palmer BF: Managing hyperkalemia caused by inhibitors of the renin-angiotensinaldosterone system. N Engl J Med 351: 585-592, 2004
13. Fagart J,HillischA,Huyet J,Bärfacker L, Fay M, Pleiss U, Pook E, Schäfer S, Rafestin-OblinME, Kolkhof P: A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule. J Biol Chem 285: 29932-29940, 2010
14. Pitt B, Kober L, Ponikowski P, Gheorghiade M, Filippatos G, Krum H, Nowack C, Kolkhof P, KimSY, Zannad F: Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur Heart J 34: 2453-2463, 2013
15. Himmelfarb J, McMonagle E, Freedman S, Klenzak J, McMenamin E, Le P, Pupim LB, Ikizler TA; The PICARD Group: Oxidative stress is increased in critically ill patients with acute renal failure. J Am Soc Nephrol 15: 2449-2456, 2004
16. Caprio M, Newfell BG, la Sala A, Baur W, Fabbri A, Rosano G, Mendelsohn ME, Jaffe IZ: Functional mineralocorticoid receptors in human vascular endothelial cells regulate intercellular adhesionmolecule-1 expression and promote leukocyte adhesion. Circ Res 102: 1359-1367, 2008
17. Callera GE, Touyz RM, Tostes RC, Yogi A, He Y, Malkinson S, Schiffrin EL: Aldosterone activates vascular p38MAP kinase and NADPH oxidase via c-Src. Hypertension 45: 773-779, 2005
18. Leopold JA, DamA,Maron BA, ScribnerAW, Liao R, Handy DE, Stanton RC, Pitt B, Loscalzo J: Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activity. Nat Med 13: 189-197, 2007
19. Wilhelm SM, SimonsonMS, RobinsonAV, Stowe NT, Schulak JA: Endothelin up-regulation and localization following renal ischemia and reperfusion. Kidney Int 55: 1011-1018, 1999
20. Liu S, Premont RT, Kontos CD, Huang J, RockeyDC: Endothelin-1 activates endothelial cell nitric-oxide synthase via heterotrimeric G-protein betagamma subunit signaling to protein jinase B/Akt. J Biol Chem278: 49929-49935, 2003
21. Mazzuca MQ, Khalil RA: Vascular endothelin receptor type B: structure, function and dysregulation in vascular disease. Biochem Pharmacol 84: 147-162, 2012
22. Ishikawa K, Ihara M,Noguchi K,Mase T,Mino N, Saeki T, Fukuroda T, Fukami T, Ozaki S, Nagase T, NishikibeM, YanoM: Biochemical and pharmacological profile of a potent and selective endothelin B-receptor antagonist, BQ-788. Proc Natl Acad Sci U S A 91: 4892-4896, 1994
23. Kuro T, Kohnou K, Kobayashi Y, Takaoka M, Opgenorth TJ, Wessale JL, Matsumura Y: Selective antagonism of the ETA receptor, but not the ETB receptor, is protective against ischemic acute renal failure in rats. Jpn J Pharmacol 82: 307-316, 2000
24. Okamoto Y, Ninomiya H, Tanioka M, Sakamoto A, Miwa S, Masaki T: Palmitoylation of human endothelinB. Its critical role in G protein coupling and a differential requirement for the cytoplasmic tail by G protein subtypes. J Biol Chem 272: 21589-21596, 1997
25. Maron BA, Zhang YY, White K, Chan SY, Handy DE,Mahoney CE, Loscalzo J, Leopold JA: Aldosterone inactivates the endothelin-B receptor via a cysteinyl thiol redox switch to decrease pulmonary endothelial nitric oxide levels and modulate pulmonary arterial hypertension. Circulation 126: 963-974, 2012
26. Rafikov R, Fonseca FV, Kumar S, Pardo D, Darragh C, Elms S, FultonD, Black SM: eNOS activation and NO function: structural motifs responsible for the posttranslational control of endothelial nitric oxide synthase activity. J Endocrinol 210: 271-284, 2011
27. Barrera-Chimal J, Pérez-Villalva R, Ortega JA, Uribe N, Gamba G, Cortés-González C, Bobadilla NA: Intra-renal transfection of heat shock protein 90 alpha or beta (Hsp90a or Hsp90b) protects against ischemia/reperfusion injury. Nephrol Dial Transplant 29: 301-312, 2014
28. Kwon O, Hong SM, Ramesh G: Diminished NO generation by injured endothelium and loss of macula densa nNOS may contribute to sustained acute kidney injury after ischemia-reperfusion. Am J Physiol Renal Physiol 296: F25-F33, 2009
29. Schupp N, Kolkhof P, Queisser N, Gärtner S, Schmid U, Kretschmer A, Hartmann E, Oli RG, Schäfer S, Stopper H: Mineralocorticoid receptor-mediated DNA damage in kidneys of DOCA-salt hypertensive rats. FASEB J 25: 968-978, 2011